SCHEMBL18979892

SCHEMBL18979892

Nc1ccc(N(CCN(c2ccccc2)c2ccc(N)cc2)c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.62
MAPT P10636 5/20 0.62
TDP1 Q9NUW8 4/20 0.62
ALDH1A1 P00352 4/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
CYP1A2 P05177 2/20 0.62
CYP2C9 P11712 2/20 0.62
CYP2C19 P33261 2/20 0.62
KDM4E B2RXH2 1/20 0.62
CYP2D6 P10635 1/20 0.62
TSHR P16473 2/20 0.46
MAOB P27338 5/20 0.44
MAOA P21397 4/20 0.44
TAAR1 Q96RJ0 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPK1 P28482 2/20 0.43
PSMD14 O00487 1/20 0.43
RECQL P46063 1/20 0.43
GFER P55789 1/20 0.43
KCNH2 Q12809 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18979908 0.89 CYP3A4 (0.56) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
SCHEMBL257146 0.88 MAOA (0.61) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
SCHEMBL28958670 0.87 CYP3A4 (0.54) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
SCHEMBL7062571 0.87 CYP3A4 (0.59) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
SCHEMBL4194791 0.84 KCNH2 (0.52) ALDH1A1L3MBTL1KDM4ETAAR1KCNH2
SCHEMBL2444795 0.84 ALDH1A1 (0.55) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
Methane SCHEMBL28942758 0.82 TDP1 (0.48) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
SCHEMBL2440814 0.82 ALDH1A1 (0.53) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
SCHEMBL5843310 0.82 CYP3A4 (0.64) CYP3A4MAPTTDP1ALDH1A1L3MBTL1
SCHEMBL10425499 0.82 KCNH2 (0.50) ALDH1A1L3MBTL1KDM4ETAAR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3792245-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS Eastman Chemical Company (US) 2021-03-17 EP claimed
EP-3634937-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY Eastman Chemical Company (US) 2020-04-15 EP claimed
EP-3634938-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING AN ANTIDEGRADANT AND ANTIFATIGUE EFFICACY Eastman Chemical Company (US) 2020-04-15 EP claimed
US-10428009-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy EASTMAN CHEMICAL COMPANY (US) 2019-10-01 US claimed
US-10287418-B2 Compounds with antidegradant and antifatigue efficacy and compositions including said compounds EASTMAN CHEMICAL COMPANY (US) 2019-05-14 US claimed
US-10160845-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy EASTMAN CHEMICAL COMPANY (US) 2018-12-25 US claimed
WO-2018226375-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING AN ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2018-12-13 WO claimed
WO-2018226376-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2018-12-13 WO claimed
EP-3394028-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS Eastman Chemical Company (US) 2018-10-31 EP claimed
US-20170275233-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US claimed
US-20170275238-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US claimed
WO-2017112440-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2017-06-29 WO claimed
US-20170174615-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2017-06-22 US claimed
EP-3634939-B1 METHODS OF MAKING COMPOUNDS HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEM CO (US) 2021-03-24 EP disclosed
EP-3792245-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS Eastman Chemical Company (US) 2021-03-17 EP disclosed
EP-3394028-B1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEM CO (US) 2020-11-04 EP disclosed
US-20170275234-A1 METHODS OF MAKING COMPOUNDS HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US disclosed
US-20170275238-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY EASTMAN CHEMICAL COMPANY (US) 2017-09-28 US disclosed
WO-2017112440-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2017-06-29 WO disclosed
US-20170174615-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428009-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy ACHE, DDO, BCHE CYP3A4 498/4885MAPT 1163/4885TDP1 116/4885
US-10160845-B2 Methods of making compounds and mixtures having antidegradant and antifatigue efficacy ACHE, BCHE, DDO CYP3A4 468/4885MAPT 1096/4885TDP1 61/4885
US-20170275234-A1 METHODS OF MAKING COMPOUNDS HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY ACHE, HNMT, PNMT CYP3A4 555/4885MAPT 1355/4885TDP1 91/4885
US-20170275238-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY ACHE, BCHE, DDO CYP3A4 468/4885MAPT 1096/4885TDP1 61/4885
US-20170174615-A1 COMPOUNDS WITH ANTIDEGRADANT AND ANTIFATIGUE EFFICACY AND COMPOSITIONS INCLUDING SAID COMPOUNDS ACHE, HDAC3, PON1 CYP3A4 166/4885MAPT 2400/4885TDP1 95/4885
US-20170275233-A1 METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY ACHE, DDO, BCHE CYP3A4 498/4885MAPT 1163/4885TDP1 116/4885
US-10287418-B2 Compounds with antidegradant and antifatigue efficacy and compositions including said compounds ACHE, HDAC3, PON1 CYP3A4 166/4885MAPT 2400/4885TDP1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.